NCT00425347View on ClinicalTrials.gov

Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

July 31, 2009

Conditions
Multiple Myeloma
Interventions
DRUG

HuLuc63

Not applicable for HuLuc63.

Trial Locations (8)

44195

Cleveland Clinic, Cleveland

48201

Wayne State University, Detroit

60611

Northwestern University Feinberg School of Medicine, Chicago

72205

Arkansas Cancer Research Center, Little Rock

90033

USC/Norris Cancer Hospital, Los Angeles

98109

Fred Hutchinson Cancer Research Center, Seattle

02115

Dana-Farber Cancer Institute, Boston

01655

University of Massachusetts Memorial Healthcare- Univ. Campus, Worcester

Sponsors

Lead Sponsor

Facet Biotech
All Listed Sponsors
lead

Facet Biotech

INDUSTRY